Pharma company SSY reports HK$910m profit

Wednesday, March 13, 2019

Pharmaceutical company SSY (2005) said net profit grew by 37.2 percent year-on-year to HK$910 million.

Revenue increased by 35.9 percent from 2017 to HK$4.18 billion. Gross profit margin improved by 3.6 percentage points to 62.3 percent.

The board declared a final dividend of 5 HK cents, up 25 percent from 2017.

Intravenous infusion solution revenue was up by 36.8 percent to HK$4.08 billion. Medical materials revenue grew by 16.2 percent to HK$154.39 million.